Various autoantibodies are seen in idiopathic inflammatory myopathies. Among myositisspecific antibodies, antiaminoacyltRNA synthetase and antimelanoma differentiationassociated protein 5 (MDA5) antibodies are associated with interstitial lung disease (ILD). AntiMDA5 anti bodies are associated with dermatomyositis (DM) or clinically amyopathic DM complicated with rapidly progressive ILD. In antiMDA5positive patients, a random groundglass attenuation pattern is a characteristic finding of ILD in chest highresolution computed tomography. Conversely, antiaminoacyl tRNA synthetase antibodies are not associated with rapidly progressive ILD but with chronic ILD. DM or clinically amyopathic DM patients with anti MDA5, and characteristic highresolution computed tomography findings are highly likely to have devastating ILD and need aggressive treatment.
Introduction
The term idiopathic inflammatory myopathy (IIM) appeared in Bohan and Peter's 1 review in 1975. They classified IIM into the following five subgroups: polymyositis (PM), dermatomyo sitis (DM), cancerassociated myositis (CAM), juvenile DM, and overlap syndrome (OS); these terms are not identical to the original names given by Bohan and Peter because they were subsequently modified by Euwer and Sontheimer.
2 Because various autoantibodies have been detected, IIM is considered an autoimmune disease whose main target organs are muscles and skin. In 1991, Dalakas 3 suggested incorporating inclusion body myositis (IBM) in the IIM group. However, it is still controversial whether IBM is an autoimmune disease. Pluk et al. 4 reported anticytosolic 5′nucleotidase 1A antibodies found in 33% of sporadic IBM patients. However, recently, Herbert et al. 5 reported that anticytosolic 5′nucleotidase 1A antibodies are detected in other autoimmune diseases and are not specific to IBM. In 1993, Euwer and Sontheimer 2 sug gested adding amyopathic DM (ADM) to the IIM group. ADM lacks muscle symptoms but is characterized by a pathognomonic skin rash of DM and is considered an estab lished category associated with DM.
Approximately 50% of IIM patients are complicated with interstitial lung disease (ILD), and having ILD is related to poor prognosis. In this review, several biomarkers and auto antibodies of ILD complicated with IIM are introduced, and their application to diagnosis and treatments is discussed.
Autoantibodies in IIM
Autoantibodies detected in IIM are divided into two categories, myositisspecific antibodies (MSA) and myositisassociated antibodies (MAA). MSA and MAA are associated with spe cific symptoms and clinical features (Table 1) . [6] [7] [8] The asso ciation between MSA and symptoms was reported by Love et al. 9 They investigated the association between MSA and clinical features in 212 adult IIM patients and found that anti aminoacyltRNA synthetase (ARS) antibodies are associated with antisynthetase syndrome, while antisignal recogni tion particle (SRP) antibodies are associated with refractory PM, and antiMi2 antibodies are associated with a certain skin rash of DM. They suggested a new approach to classify IIM using MSA. The concept of classification of IIM using MSA has been supported by the discoveries of antimelanoma differentiationassociated protein 5 (MDA5) antibodies associated with ADM 10 and antitranscription intermediary factor 1γ/α (TIF1γ/α) antibodies associated with CAM. , each patient had a single type of MSA. Distinct from MSA, MAA are not specific to IIM patients. AntiU1RNP antibodies are major MAA and detected in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), PM, and mixed connective tissue dis ease. AntiPM/Scl antibodies 12 are also seen in various con nective tissue diseases, such as PMSSc OS, PM, DM, SSc, SLE, and undifferentiated connective tissue disease (UCTD). In our analysis of six antiKupositive patients, two had PM SLE OS, two had SLE, one had PM, and one had UCTD. Taken together, MAA can be seen in patients with myopathy complicated with other connective tissue diseases.
biomarkers Associated with ILd in IIM serum lactate dehydrogenase, KL-6, and surfactant protein d. Serum lactate dehydrogenase (LDH), KL6, and serum surfactant protein D (SPD) reflect lung damage and are universal activity markers of ILD and can also be bio markers of ILD complicated with IIM. Serum LDH is a clas sical activity marker of ILD, although it is less specific for lung lesions than serum KL6 and SPD. KL6 is a mucin like high molecular weight glycoprotein expressed in type II alveolar pneumocytes and bronchiolar epithelial cells. Fathi et al. 13 reported that the serum KL6 level was significantly higher in PM/DM patients with ILD than in PM/DM patients without ILD (sensitivity: 83% and specificity: 100%) and serum KL6 level reflected pulmonary functional reserve in PM/DM patients with ILD. Ihn et al. 14 reported that serum SPD level was also significantly higher in PM/DM patients with ILD than in PM/DM patients without ILD and the serum SPD level was inversely correlated with percent vital capacity and percent diffusing capacity of the lungs for carbon monoxide.
serum ferritin and interleukin-18. Gono et al reported that the serum ferritin level was elevated in antiMDA5 positive clinically ADM (CADM) or DM patients 15 and cor related with severity (AaDO 2 and P/F ratio), 15 prognosis, 15 and disease activity of ILD in antiMDA5positive CADM or DM patients. In addition, serum interleukin18 level was sig nificantly correlated with response to therapy and prognosis of ILD in those patients. 16 These findings imply that macrophage activation plays an important role in the pathophysiology of ILD in antiMDA5positive patients.
Autoantibodies Associated with ILd in IIM
Anti-Ars antibodies. AntiARS antibodies are seen in 25%-42% of all myositis patients 6, 7 and are also detected in patients with IIM or idiopathic interstitial pneumonia (IIP). 17 ARS is essential when messenger RNA is translated to amino acids. The definition of antiARS antibodies includes not only their binding ability to ARS but also their blocking ability against the function of ARS. [18] [19] [20] [21] There have been reports of antiJo1, 18 antiPL7, 19 antiPL12, 20 antiEJ, 21 anti OJ, 21 and antiKS antibodies, which correspond to histidyl, threonyl, alanyl, glycyl, isoleucyl, and asparaginyltRNA synthetases, respectively. Love et al. 9 described five common symptoms, namely ILD, Raynaud's phenomenon, polyarthri tis, high fever, and mechanic's hand, seen in antiARSpositive IIM patients and named them as antisynthetase syndrome. AntiARS antibodies may have stronger connections with ILD than with myopathy. A significant association of antiARS antibodies with ILDpreceding IIM patients has been reported (Fig. 1) . 22 Moreover, antiARS antibodies have been found in ILD patients without myopathy. 17, 22 Watanabe et al. 23 examined the histopathology of lungs sampled from eight antiARSpositive ILDalone patients. Three patients showed cellular nonspecific interstitial pneumonia, three patients showed fibrous nonspecific interstitial pneumonia, and two patients showed usual interstitial pneumonia with cellular infiltration. 23 They also reported that chest high resolution computed tomography (HRCT) revealed traction bronchiectasis, groundglass opacity, lower reticulation, and subpleural sparing (Fig. 2) , while honeycombing was not observed. 23 Additionally, shrinking lung is also a common finding of chest Xray in antiARSpositive ILD patients.
ILD complicated by antiARSpositivity responds to immunosuppressive therapy but tends to show a recurrent clinical course. ILD in antiARSpositive patients showed a more favorable response to glucocorticoid therapy than in anti ARSnegative patients, 22 and a recurrent course of ILD was significantly more frequent in the antiARSpositive patients than in the antiARSnegative patients. 22 These results imply that antiARS antibodies can be markers for clinical course prediction of ILD complicated with IIM. Indication of immunosuppressants, such as oral tacrolimus and intravenous cyclophosphamide, should be considered in patients with recurrent ILD complicated with IIM.
Hamaguchi et al. 24 investigated the difference in clini cal features among patients positive for each kind of anti ARS antibodies. ILDalone cases were frequent in patients with antiPL12, antiOJ, and antiKS, while myopathy and rash were frequent in patients with antiJo1, antiPL7, and antiEJ. Polyarthritis is more strongly associated with anti Jo1 than with nonJo1 antiARS antibodies. 24 , 25 Aggarwal et al. 25 reported that fiveyear survival was lower in patients with nonJo1 antiARS antibodies than in patients with anti Jo1 antibodies.
Recently, we established a new ELISA system (MESA CUP™ AntiARS Test; MBL Co., Ltd.) that covers anti Jo1, antiPL7, antiPL12, antiEJ, and antiKS antibodies simultaneously, 17 and it is used daily in Japan. To diagnose IIM or idiopathic interstitial pneumonia, its sensitivity is 22.7% (95/418), and its specificity is 97.7% (299/306), using a cutoff level of 25 U/mL. The limitation of the system is that it cannot identify the kind of antiARS antibodies or antiOJ.
Anti-MdA5 antibodies. Sontheimer 26 enlarged the category of ADM and referred the entity of CADM that includes hypomyopathic DM with typical rashes and subclinical myopathy. The study did not mention patients with rapidly progressive and fatal ILD and required a twoyear observation with no evident myopathy to diagnose CADM. However, several cases of CADM complicated with deva stating ILD have been reported from Asia and also from the USA 27 and Europe. 28 Those patients were refractory to immunosuppressive therapy leading to a fatal clinical course, and histopathology of the autopsied lungs showed diffuse alveolar damage. In 2005, Sato et al found anti140 kDa antibodies in Japanese CADM patients, 29 and finally, MDA5 was identified as its target antigen.
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AntiMDA5 antibodies are detected in CADM or DM patients. 10, 15, 27, 28, 30 ILD is seen in 50%-100% of the anti MDA5positive CADM or DM patients.
10,27,28,30 Tanizawa et al. 31 reported that the findings of chest HRCT were dom inated by (i) lower consolidation or groundglass attenuation pattern and (ii) a random groundglass attenua tion pattern (Fig. 3) . Mortality ranged from 36% to 46% in antiMDA5 positive CADM or DM patients. 10, 15 If an antiMDA5pos itive patient shows even slowly progressive ILD, the most intensive immunosuppressive regimen should be considered to prevent ILD from advancing to a devastating status. Importantly, Teruya et al. 32 reported that an antiMDA5 positive ADM patient with rapidly progressive ILD was suc cessfully treated with polymyxinB direct hemoperfusion.
The titer of antiMDA5 antibodies reflects the severity of ILD and skin ulcerations. 30 Cao et al. 30 reported that the titer of antiMDA5 antibodies reflected the HRCT score of lung legions, and the titer was decreased after treatment. Anti-U1-rNP antibodies. AntiU1RNP antibodies are found in major MAA associated with OS or mixed con nective tissue disease and are associated with both myopathy and ILD. 33 The frequency ranges from 6% to 10% in all myositis. 7, 8 In general, ILD progresses chronically in anti U1RNPpositive patients. Glucocorticoids are effective in treating ILD in antiU1RNPpositive patients.
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Anti-PM/scl antibodies. The prognosis of ILD in antiPM/Sclpositive patients cannot be determined currently because of the limited number of studies pub lished. However, Muro et al. 35 reported that 4 of the 11 patients positive for antiPM/Scl antibodies (two DM, one CADM, and one UCTD) had ILD. All of them required immunosuppressive therapy, although they did not show fatal outcomes.
Anti-Ku antibodies. The clinical course of ILD in anti Kupositive patients is also uncertain because the number of reports is limited. Rigolet et al. 36 reported that 11 of the 30
antiKupositive patients (mostly with IIM) had ILD. Eight of the 11 antiKupositive patients with ILD received immuno suppressive therapy; however, their ILD was resistant to the therapy in six of the eight patients.
Application of biomarkers and Autoantibodies to treatments
According to the profiles of autoantibodies, ILD complicated with IIM can be divided into three groups: high, moderate, and lowrisk groups. High-risk group: anti-MdA5 antibodies. Decisions for treatment. In the patients with antiMDA5 antibodies, treat ment should begin before respiratory symptoms or impaired pulmonary function develops. When an antiMDA5pos itive patient shows characteristic chest HRCT findings and elevated biomarkers, such as serum LDH, KL6, SPD, and ferritin, the most aggressive immunosuppressive treatments should commence.
Follow-up. Symptoms, oxygenation status, image find ings, serum LDH, KL6, and SPD will be measures of ther apeutic effects. Serum ferritin, interleukin18, and the titer of antiMDA5 antibodies may reflect the activity of ILD in anti MDA5positive patients.
Moderate-risk group: anti-Ars, anti-U1-rNP, anti-PM/scl, and anti-Ku antibodies. Decisions for treatment. Respiratory symptoms, speed of reduction in pulmonary func tion, and speed of expansion of chest HRCT findings should be taken into consideration to determine when to start immu nosuppressive treatments.
Follow-up. Symptoms, pulmonary function, image find ings, and universal activity markers of ILD (serum LDH, KL6, and SPD) are helpful to evaluate the potential outcomes of treatment. AntiARSpositive patients occasionally show recurrent ILD; therefore, careful attention is needed to detect any disease recurrence. Immunosuppressants should be conside red in patients with recurrent ILD complicated with IIM.
Low-risk group: anti-Mi-2, anti-srP, and anti-tIF1-γ/α antibodies. Decisions for treatment. Treatment should fol low the same course as the moderaterisk group. However, because ILD is less common in patients with antiMi2, 37 antiSRP, 38 or antiTIF1γ/α antibodies, 39 careful consider ation is needed before treating ILD in these patients. Possible overlap with other conditions including infectious or drug induced pneumonia should be examined. 
